In addition to the current focus on tyrosine kinase inhibitors, it is equally pertinent to consider the potential role of other EGFR inhibitors such as monoclonal antibodies (mAbs) like cetuximab and panitumumab in NSCLC treatment. Here, EGFR is linked to non-small cell lung carcinoma.